Platyphylline (Platyphyllin)

Composition Pharmacodynamics Indications Carefully Contraindications Dosing and Administration Side effects Form release / dosage
Read on
Active substancePlatyphyllinePlatyphylline
Similar drugsTo uncover
  • Platyphylline
    pills inwards 
    VIFITEH, CJSC     Russia
  • Platyphylline
    solution PC 
    VEROPHARM SA     Russia
  • Platyphylline
    solution PC 
    MICROGEN FGUP Scientific and Production Association     Russia
  • Platyphylline
    solution PC 
    VIFITEH, CJSC     Russia
  • Platyphylline
    solution PC 
    MOSCOW ENDOCRINE FACTORY, FSUE     Russia
  • Platyphylline
    solution PC 
    MOSHIMFARM PREPARATES them. N.А.Semashko, OJSC     Russia
  • Platifillin hydrotartrate
    solution PC 
    NOVOSIBHIMFARM, OJSC     Russia
  • Platifillin hydrotartrate
    solution PC 
    DALHIMFARM, OJSC     Russia
    • Dosage form: & nbsp

    Solution for subcutaneous administration.

    Composition:

    In 1 ml of solution contains:

    Active substance: platifillin hydrotartrate - 2 mg. Excipient: water for injection.

    Description:

    Transparent colorless liquid.

    Pharmacotherapeutic group:M-holinoblokator.
    ATX: & nbsp

    A.03.A.A   Synthetic holinoblokatory - ethers with tertiary amino group

    Pharmacodynamics:

    M-holinoretseptor blocker. It has a myotropic, spasmolytic and weak sedative effect. Reduces the tone of the smooth muscles of the gastrointestinal tract (GIT), bronchi. Reduces the secretion of salivary, lacrimal, bronchial, sweat glands. Expands the pupil, causes a moderately pronounced paralysis of accommodation and increased intraocular pressure.

    Pharmacokinetics:

    Easily passes through the histohematological barriers (including BBB), cellular and synaptic membranes. When large doses are administered, it accumulates in the central nervous system at significant concentrations. Metabolised in the liver. It is subjected to hydrolysis with the formation of platinetsin and platinetic acid. It is excreted by the kidneys and intestines. Do not cumulate.

    Indications:

    Peptic ulcer of stomach and duodenum (as part of complex therapy); for relief of bouts of spasmodic pain (intestinal, hepatic, renal colic).

    Contraindications:

    Hypersensitivity, zakratougolnaya glaucoma, cachexia, severe atherosclerosis, heart failure II-III st., Arrhythmias, tachycardia; hyperplasia of the prostate; hepatic and / or renal insufficiency; pyloroduodenal stenosis, diaphragmatic hernia in combination with reflux esophagitis, paralytic ileus, intestinal atony, bleeding from the gastrointestinal tract, megacolon complicated with ulcerative colitis; elderly and senile age.

    Carefully:

    With care - cardiovascular diseases, in which an increase in heart rate may be undesirable: ciliaryarrhythmia, tachycardia, chronic heart failure, ischemic heart disease, mitral stenosis, arterial hypertension, acute bleeding; hyperthyroidism (possibly strengthening tachycardia); increased body temperature (may increase even more due to suppression of sweat gland activity); reflux-esophagitis, hernia of the esophagus of the diaphragm, combined with reflux-esophagitis (decreased esophageal and gastric motility and relaxation of the lower esophageal sphincter may contribute to a slowdown in gastric emptying and increased gastroesophageal reflux through the sphincter with impaired function, diseases of the gastrointestinal tract accompanied by obstruction: achalasia and stenosis of the pylorus (there may be a decrease in motor and tone, leading to obstruction and retention of the contents of the stomach), intestinal atony in patients elderly patients or weakened patients (possible development of obstruction), paralytic intestinal obstruction, diseases with increased intraocular pressure: closed-angle (mydriatic effect, leading to increased intraocular pressure,can cause acute attack) and open-angle glaucoma (mydriatic effect may cause some increase in intraocular pressure, correction of therapy may be required), age over 40 (risk of undiagnosed glaucoma); ulcerative colitis (high doses can inhibit intestinal peristalsis, increasing the likelihood of paralytic intestinal obstruction, and possibly the manifestation or exacerbation of such a serious complication as a toxic megacolon); dryness of the oral mucosa (long-term use may cause further intensification of xerostomia); hepatic insufficiency (decreased metabolism) and renal insufficiency (the risk of side effects due to decreased removal of platyphylline); chronic lung diseases, especially in young children and weakened patients (a decrease in bronchial secretion can lead to a thickening of the secret and the formation of congestion in the bronchi); myasthenia gravis (the condition may worsen due to the prevention of the action of acetylcholine); autonomic (autonomic) neuropathy (urinary retention and paralysis of accommodation may be intensified),hyperplasia of the prostate without obstruction of the urinary tract, urinary retention or predisposition to it, or diseases accompanied by obstruction of the urinary tract (including the bladder neck due to prostatic hyperplasia); gestosis (hypertension is possible); brain damage in children (effects from the central nervous system may increase); Down's disease (possibly an unusual dilated pupil and increased heart rate); central paralysis in children (reaction to holinoblokatory may be most pronounced).

    Pregnancy and lactation:

    Use the drug during pregnancy should be only if the expected benefit for the mother exceeds the potential risk to the fetus.

    If it is necessary to use lactation, breastfeeding should be discontinued.

    Dosing and Administration:

    With peptic ulcer of the stomach and duodenum, for the relief of bouts of spasmodic pain (intestinal, hepatic, renal colic), the drug is administered under the skin for 2-4 mg (1-2 ml of the solution 2 mg / ml). For the course treatment (10-20 days) is administered subcutaneously for 2-4 mg 2-3 times a day.

    The highest dose for adults: single dose - 10 mg, daily - 30 mg.

    Single doses for children per 1 kg of body weight: newborns and infants - 0.035 mg / kg (0.0175 ml / kg), 1-5 years - 0.03 mg / kg (0.015 ml / kg), 6-10 years - 0,025 mg / kg (0,0125 ml / kg), 11-14 years - 0,02 mg / kg (0,01 ml / kg).

    The highest daily doses for children: newborns and nurses - 0.07 mg / kg, 1-5 years - 0.06 mg / kg, 6-10 years - 0.05 mg / kg, 11-14 years - 0.04 mg / kg.

    Side effects:

    Dry mouth, thirst, lowering of arterial pressure, tachycardia, mydriasis, accommodation paralysis, intestinal atony, dizziness, headache, photophobia, convulsions; retention of urine; acute psychosis (in high doses); atelectasis of the lung.

    Overdose:

    Symptoms: paralytic intestinal obstruction, acute urinary retention (in patients with prostate adenoma), paralysis of accommodation, increased intraocular pressure; dryness of the mucous membrane of the oral cavity, nose, throat, difficulty swallowing, speech, mydriasis (until the iris completely disappears), tremor, convulsions, hyperthermia, excitation, central nervous system depression, inhibition of respiratory and vasomotor centers.

    Treatment: forced diuresis, parenteral administration of cholinostimulators and anticholinesterase drugs.At a hyperthermia - wet wipes, antipyretic agents; with excitation - iv injection of sodium thiopental or rectal-chloral hydrate; with mydriasis - topically, in the form of eye drops phosphacol, physostigmine, pilocarpine. In case of an attack of glaucoma immediately 1% solution of pilocarpine is injected into the conjunctival bag every 2 hours by 2 drops and by 1 ml of 0.05% solution of prosirin 3-4 times a day.

    Interaction:

    Strengthens the sedative and hypnotic effect of phenobarbital, pentobarbital, magnesium sulfate. Other m-holinoblokatory, amantadine, haloperidol, phenothiazine derivatives, MAO inhibitors, tricyclic antidepressants, and some H1-histamine receptor blockers increase the risk of side effects. Antagonism with cholinesterase inhibitors. Morphine increases the inhibitory effect on the cardiovascular system; MAO inhibitors - positive chrono- and batmotropic effects; cardiac glycosides - a positive Batmotrope action; quinidine, procainamide - m-cholinoblocking action.

    With pain associated with spasms of smooth muscles, can be combined with analgesic drugs, sedatives and anxiolytic drugs (tranquilizers),with vascular spasms - with hypotensive and sedative drugs.

    Effect on the ability to drive transp. cf. and fur:

    During the treatment period, it is necessary to refrain from driving vehicles and practicing other potentially hazardous activities that require an increased concentration of attention and speed of psychomotor reactions.

    Form release / dosage:

    A solution for subcutaneous administration of 2 mg / ml in ampoules of 1 ml.

    Packaging:

    For 10 ampoules with instructions for use, with an ampoule or ampoule ampoule knife in a pack or box of cardboard. When packaging ampoules that have a break ring or an opening point, the ampoule knife or the ampoule scapegrator is not put in.

    5 ampoules in a cassette outline package. 2 cassette contour packs with instructions for use in a pack of cardboard.

    Storage conditions:

    In the dark place at a temperature of 10 to 25 ° C.

    Keep out of the reach of children.

    Shelf life:

    5 years. Do not use after the expiration date printed on the package.

    Terms of leave from pharmacies:On prescription
    Registration number:LS-000656
    Date of registration:14.05.2010
    The owner of the registration certificate:MICROGEN FGUP Scientific and Production Association MICROGEN FGUP Scientific and Production Association Russia
    Manufacturer: & nbsp
    Information update date: & nbsp10.08.2015
    Illustrated instructions
      Instructions
      Up